Met Life Investment Management, LLC Biocryst Pharmaceuticals Inc Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 126,949 shares of BCRX stock, worth $994,010. This represents 0.01% of its overall portfolio holdings.
Number of Shares
126,949
Previous 119,750
6.01%
Holding current value
$994,010
Previous $910,000
4.84%
% of portfolio
0.01%
Previous 0.01%
Shares
43 transactions
Others Institutions Holding BCRX
# of Institutions
277Shares Held
167MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.9MShares$171 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$156 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$92.9 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$71.1 Million4.33% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$63.8 Million1.52% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.46B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...